Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study

• Główni autorzy: Sandra Hummel (Autor), Andreas Beyerlein (Autor), Markus Pfirrmann (Autor), Anna Hofelich (Autor), Daniela Much (Autor), Susanne Hivner (Autor), Melanie Bunk (Autor), Melanie Herbst (Autor), Claudia Peplow (Autor), Markus Walter (Autor), Denise Kohn (Autor), Nadine Hummel (Autor), Jürgen Kratzsch (Autor), Michael Hummel (Autor), Martin Füchtenbusch (Autor), Joerg Hasford (Autor), Anette-G. Ziegler (Autor), Heike Börschmann (Autor), Sophia Ebe (Autor), Eleni Giannopoulou (Autor), Minna Harsunen (Autor), Veronika Hofbauer (Autor), Andrea Schuppenies (Autor), Maike Wallner (Autor), David Wiesenäcker (Autor), Stephanie Zillmer (Autor), Lorenz Lachmann (Autor), Rüdiger Landgraf (Autor), Karl-Theo Maria Schneider (Autor), Elisabeth André (Autor), Viktoria Janke (Autor), Ezio Bonifacio (Autor)
• Format: Książka
• Wydane: Elsevier, 2018-03-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Objective: Women with insulin-requiring gestational diabetes mellitus (GDM) are at high risk of developing diabetes within a few years postpartum. We implemented this phase II study to test the hypothesis that vildagliptin, a dipeptidyl peptidase-4 inhibitor, is superior to placebo in terms of reduc...